The mission of the OSUCCC Clinical Treatment Unit and Clinical Trials Processing Laboratory Shared Resource (CTU/CTPL SR) is to advance the quality and efficiency of early phase clinical translational research. The CTU/CTPL SR is a new shared resource but has been in development since January 2004 when it was created to support and expand our ability to conduct early Phase I and II clinical trials. The CTU/CTPL SR is composed of two different but intimately related units: the Clinical Treatment Unit (CTU) and the Clinical Trials Processing Laboratory (CTPL). Historically, the CTU/CTPL SR has been funded solely with OSUCCC/institutional support. The CCSG will only support the CTPL component of the SR. The CTU is a $2 M ambulatory """"""""phase 1 unit"""""""" constructed in The James Cancer Hospital in 2004. The CTU specializes in treating cancer patients on early clinical trials requiring intense monitoring and/or complex correlative specimen collection and processing. The CTPL enhances the quality of research by providing dedicated staff for high volume procurement, processing, storage, delivery, and shipment of research specimens critical to the correlative studies component of OSUCCC clinical trials. Highly trained staff in the CTU/CTPL SR works closely with the Clinical Trials Office (CTO), Pharmacoanalytical (PhASR), Leukemia Tissue Bank (LTBSR) and Biorepository and Biospecimen (BBR) Shared Resources to provide protocol review and feasibility assessment, specimen kit assembly and distribution of specimens to internal and external research laboratories. The infrastructure of the OSUCCC CTU/CTPL SR is well established and is directly under CCC leadership. Larry Schaaf, Ph.D., Director of the Resource brings a wealth of experience to the CTU/CTPL SR with over 20 years of experience in conducting and analyzing phase I clinical correlative trials and over 55 publications. The CTU/CTPL SR has been widely used by the OSUCCC clinical research community since its inception in 2004. During this time period, the CTU has supported 83 protocols involving >850 patients and more than 10,400 patient visits and the CTPL has procured and/or processed over 35,200 patient specimens. During the past year, 21 OSUCCC members have utilized the CTU/CTPL SR for 90 projects, representing 5 of the 6 OSUCCC programs and making up 80.3% of the overall CTU/CTPL SR usage, with the remainder being utilized by clinical oncology faculty who work directly with or for OSUCCC members. An additional 41 new protocols have been identified for future support In the first half of coming year. This Shared Resource will continue to enhance the quality of clinical translational research conducted at the OSUCCC by providing improved efficiency, enhanced compliance, and cost-effective centralized support of eerily phase correlative studies.

Public Health Relevance

The Ohio State University Comprehensive Cancer Center (OSUCCC) Clinical Treatment Unit/Clinical Trials Processing Laboratory Shared Resource (CTU/CTPL SR) provides a stable, reliable, and cost-effective,state-of-the art unit for conducting eariy phase clinical trials requiring intense monitoring and/or complex correlative specimen collection. It also provides high quality, high volume specimen processing, short-term storage and distribution of liquid specimens for pharmacokinetics or other biomarkers collected as correlative components of phase I and II translational clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601814
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$169,433
Indirect Cost
$58,330
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fazio, Nicola; Buzzoni, Roberto; Baudin, Eric et al. (2016) A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res 36:713-9
Eloy, Josimar O; Petrilli, Raquel; Topan, José Fernando et al. (2016) Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces 141:74-82
Byrd, John C; Flynn, Joseph M; Kipps, Thomas J et al. (2016) Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 127:79-86
Datta, Jharna; Islam, Mozaffarul; Dutta, Samidha et al. (2016) Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 56:32-9
Wang, Hai; Agarwal, Pranay; Zhao, Shuting et al. (2016) Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials 97:62-73
Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:
Rai, K; Pilarski, R; Cebulla, C M et al. (2016) Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 89:285-94
Kerrigan, Kathleen; Shoben, Abigail; Otterson, Gregory (2016) Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer 17:523-527
DiSilvestro, David J; Melgar-Bermudez, Emiliano; Yasmeen, Rumana et al. (2016) Leptin Production by Encapsulated Adipocytes Increases Brown Fat, Decreases Resistin, and Improves Glucose Intolerance in Obese Mice. PLoS One 11:e0153198
Terakawa, Jumpei; Rocchi, Altea; Serna, Vanida A et al. (2016) FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower Müllerian Duct. Mol Endocrinol 30:783-95

Showing the most recent 10 out of 1929 publications